EMA OKs First Digital Outcome As Primary Endpoint In Duchenne Studies
Digital Endpoint Can Be Used As An Alternative To The 6 Minute Walking Test
A digital outcome for measuring the top walking speed of patients at home that can be captured using wearable devices has been approved by the European Medicines Agency as an alternative primary endpoint in ambulatory Duchenne Muscular Dystrophy studies.
